An assessment model for the efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk

Affiliations

• ¹ Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
• ² Department of Hematology, Ningbo NO.2 Hospital, Ningbo, Zhejiang 315010, China.
• ³ Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
• ⁴ Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.